Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Dipharma
Dipharma
Activities:
Ingredients
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Manufacturing
Dipharma expands CDMO offering with new QC lab in the US
New lab has enabled Italy-based Dipharma to now offer full services from discovery to marketed drugs
Manufacturing
Dipharma Francis Srl sell Amino Chemicals to ABA Chemicals
Dipharma Francis Srl, a European manufacturer of Active Pharmaceutical Ingredients, completed the sale of its subsidiary Amino Chemicals, based in Malta, to ABA Chemicals Corporation, China
Research & Development
New room-temperature stable Carglunic acid tablets
Carglumic acid is a therapeutic tool in the management of inborn metabolic disorders affecting the urea cycle
Pharmaceutical
Disanit authorised for marketing in Europe
Dipharma's Disanit (Nitisinone capsules 2, 5 and 10mg) is now under marketing authorisation (MA) evaluation in the EU.
Distribution
Dipharma and Alvogen launch Diterin in South Korea
First drug commercially available for the treatment of hyperphenylalaninemia due to phenylketonuria
Subscribe now